Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled verapamil for pulmonary artery systolic pressure in COPD
IRCT20230804059027N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of verapamil in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH), sponsored by Tehran University of Medical Sciences. Primary endpoint: Change in pulmonary artery systolic pressure. Started Aug 2023; status: completed.
02
Drugs
verapamil
03
Conditions
chronic obstructive pulmonary disease (COPD)pulmonary hypertension (PH)
Beyond the preview
Go deeper on IRCT20230804059027N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230804059027N1.